Drug Profile
SCD 101
Alternative Names: SCD101Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Invenux LLC
- Developer Invenux LLC; State University of New York
- Class Antianaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Beta-thalassaemia in USA (PO, Capsule)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in USA (PO, Capsule)
- 03 Dec 2016 Adverse events data from a phase Ia trial in Sickle cell anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)